Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 1;84(1):2-7.
doi: 10.1093/jnen/nlae113.

New criteria to predict LATE-NC in the clinical setting: Probable/Possible LATE and LANS

Affiliations
Review

New criteria to predict LATE-NC in the clinical setting: Probable/Possible LATE and LANS

Peter T Nelson. J Neuropathol Exp Neurol. .

Abstract

This review discusses terminology recently proposed for the classification of dementia and, more specifically, nosology related to aging-associated TDP-43 pathology: limbic-predominant age-related TDP-43 encephalopathy (LATE), and limbic-predominant amnestic neurodegenerative syndrome (LANS). While the "gold standard" for these clinical conditions is still LATE neuropathologic changes (LATE-NC), clinical criteria and biomarkers are evolving. The newly proposed clinical rubrics are discussed with emphasis on the need for terminology that acknowledges the distinctions between clinical syndrome-, molecular biomarker-, and pathologically defined disease concepts. As further progress is made on research into the specific biomarker-based detection and prediction of TDP-43 proteinopathy in the clinical setting, the definitions of "Probable" and "Possible" LATE are likely to become more useful clinically. For people interested in the pathological diagnoses or basic research related to LATE-NC, the relevant terminology remains unchanged by the newly proposed clinical criteria.

Keywords: Alzheimer disease and related dementia (ADRD); FDG-PET; LATE-NC; TDP-43; amnesia; biomarker; dementia.

PubMed Disclaimer

Conflict of interest statement

None declared.

Similar articles

Cited by

References

    1. Petersen RC, Weintraub S, Sabbagh M, et al.; Dementia Nomenclature Initiative. A new framework for dementia nomenclature. JAMA Neurol. 2023;80:1364-1370. - PubMed
    1. Knopman DS, Petersen RC, Jack CR Jr. A brief history of “Alzheimer disease”: multiple meanings separated by a common name. Neurology. 2019;92:1053-1059. - PMC - PubMed
    1. Knopman DS, Haeberlein SB, Carrillo MC, et al. The National Institute on Aging and the Alzheimer’s Association Research Framework for Alzheimer’s disease: perspectives from the Research Roundtable. Alzheimers Dement. 2018;14:563-575. - PMC - PubMed
    1. Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology—recommendations from the Global CEO Initiative on Alzheimer’s Disease. Nat Rev Neurol. 2024;20:426-439. - PubMed
    1. Chetelat G, Baron JC. Early diagnosis of Alzheimer’s disease: contribution of structural neuroimaging. Neuroimage. 2003;18:525-541. - PubMed

Supplementary concepts